A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Trial of Intravenous Zotatifin in Adults With Mild or Moderate Coronavirus Disease 2019 (COVID-19)
Latest Information Update: 23 Oct 2023
At a glance
- Drugs Zotatifin (Primary) ; Zotatifin (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions
- Acronyms PROPEL
- Sponsors Effector Therapeutics
- 04 Oct 2023 Status changed from active, no longer recruiting to completed.
- 16 May 2023 Planned End Date changed from 1 Apr 2023 to 30 Jul 2023.
- 22 Feb 2023 Results assessing safety, antiviral activity, and PK of zotatifin in non-hospitalized patients (pts) with mild/moderate COVID presented at the 30th Conference on Retroviruses and Opportunistic Infections 2023